Dr. Geynisman on Patient Preferences for Treatment of RCC

Daniel M. Geynisman, MD
Published: Tuesday, Oct 31, 2017



Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

According to Geynisman, patients are very motivated and interested in participating in clinical trials of immunotherapy.

Patients can derive tremendous benefit for a long time from immunotherapy, which is very different from most treatments, states Geynisman.
 


Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

According to Geynisman, patients are very motivated and interested in participating in clinical trials of immunotherapy.

Patients can derive tremendous benefit for a long time from immunotherapy, which is very different from most treatments, states Geynisman.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x